9 OHSU investigators receive Biomedical Innovation awards

The Oregon Clinical and Translational Research InstituteOHSU Technology Transfer and OHSU Collaborations & Entrepreneurship have announced six awardees to two tracks of the Biomedical Innovation Program: COVID-19 Rapid Response and Digital Health.

The COVID-19 Rapid Response program awardees are:

Above, clockwise from top left: Ellen Tilden, Ph.D.; Fikadu Tafesse, Ph.D.; Timur Mitin, M.D,, Ph.D.; Bory Kea, M.D.; Wencesley Paez, M.D.; Peter Schulman, M.D.; and Albert Chi, M.D.

  • Albert Chi, M.D.: “OHSU 3D Printed CRISIS Ventilator”
  • Bory Kea, M.D.: “Evaluating the use of brown paper bags for storage of limited re-usable PPE exposed to SARS-CoV-2COVID-19 Rapid Response”
  • Fikadu Tafesse, Ph.D.: “SARS-CoV-2 Nanobodies as Therapeutics Against COVID-19”

The Digital Health Program awardees are:

Two of the COVID-19 projects will be supported by the IDEA Fund, which is a newly-founded fund. One COVID-19 project and all of the Digital Health projects will be supported by the OHSU University Venture Development Fund. Both of these funds were made possible through philanthropic giving.

The BIP COVID-19 Rapid Response awardees are addressing the pandemic through projects studying 3D printed ventilators, reusable PPE and SARS-CoV 2 nanobodies. The Digital Health awardees will focus on digital solutions for cardiac and pulmonary disease, postpartum depression and bone metastases.

For the COVID-19 projects, the BIP called for multidisciplinary basic or clinical research across the translational spectrum that directly addressed COVID-19, and awarded the above projects based on their abilities to make both a significant and potentially quick impact.

The Digital Health program awards projects that use technology to improve healthcare delivery and advance biomedical research. The BIP looks for projects that focus on quality of patient care and research efficiency and have commercialization potential.

“Digital Health is a rapidly growing area of medicine and one that the Biomedical Innovation Program can support to help move the needle for promising projects at OHSU,” said OCTRI Director David Ellison, M.D. “This funding, along with project management and mentorship, can put these technologies in the best possible position for commercialization where they can ultimately improve patient outcomes.”

The Biomedical Innovation Program is also supported by OHSU Research and Innovation.